abiraterone vs leuprolide

PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.

Side-by-side comparison of abiraterone and leuprolide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.

Drug Class
abiraterone CYP17 Inhibitor
leuprolide GnRH Agonist
Type
abiraterone Prescription
leuprolide Prescription
Summary
abiraterone

Abiraterone (Zytiga) is a medicine used with prednisone to treat prostate cancer that has spread. It works by lowering the amount of androgen your body makes.

leuprolide

VABRINTY is a medicine that treats advanced prostate cancer. It contains leuprolide, which lowers testosterone levels.

What It Treats
abiraterone

Abiraterone is used to treat prostate cancer that has spread to other parts of the body. It is for cancers that are castration-resistant, meaning they no longer respond to hormone therapy alone. It is also used for high-risk castration-sensitive prostate cancer. You will take this medicine with prednisone.

leuprolide

VABRINTY treats advanced prostate cancer in men. Prostate cancer is when cells in the prostate gland grow out of control. This medicine helps to slow down the growth of the cancer.

How It Works
abiraterone

Abiraterone blocks an enzyme called CYP17, which your body needs to make androgens. Androgens can help prostate cancer grow. By blocking this enzyme, abiraterone lowers androgen levels and slows cancer growth.

leuprolide

VABRINTY contains leuprolide, which is a GnRH agonist. It lowers the amount of testosterone your body makes. This can help to slow the growth of prostate cancer cells.

Common Side Effects
abiraterone
  • Feeling tired
  • Joint pain
  • High blood pressure
  • Feeling sick to your stomach
  • Swelling
leuprolide
  • Feeling tired or weak
  • Hot flashes or sweats
  • Testicles shrinking
FAERS Reports
abiraterone
  • Death 1,390
  • Fatigue 1,023
  • Hot Flush 678
  • Asthenia 562
  • Disease Progression 561
leuprolide
  • Fatigue 82
  • Nausea 61
  • Headache 58
  • Malignant Neoplasm Progression 53
  • Disease Progression 50
Serious Warnings
abiraterone

Abiraterone can cause problems with mineralocorticoid excess, like high blood pressure, low potassium, and fluid retention. If you have heart problems, your doctor will monitor you closely. This medicine can also cause liver problems, which can be severe. Your doctor will check your liver function regularly. Do not take abiraterone with radium Ra 223 dichloride. Abiraterone can harm an unborn baby, so men should use effective birth control if their partner can get pregnant.

leuprolide

VABRINTY can cause a temporary increase in testosterone levels, which may worsen symptoms at first. This could include bone pain, nerve problems, or trouble urinating. VABRINTY may also increase your risk of high blood sugar, diabetes, heart problems, and seizures. Tell your doctor right away if you have signs of a severe skin reaction.

Pregnancy
abiraterone

Abiraterone can cause harm to an unborn baby. Men who are taking abiraterone should use effective birth control during treatment and for 3 weeks after the last dose if their partner is able to get pregnant. It is not known if abiraterone passes into breast milk.

leuprolide

VABRINTY can harm an unborn baby. Females should not take VABRINTY if they are pregnant or may become pregnant. It is not known if VABRINTY passes into breast milk, so talk to your doctor about breastfeeding.

Also Compare, Nearby Drugs

Compare leuprolide with

How to Read This abiraterone vs leuprolide Comparison

abiraterone is classified in the CYP17 Inhibitor drug class, while leuprolide sits within the GnRH Agonist class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.

Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, abiraterone has 4,214 submissions while leuprolide has 304. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.

A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for abiraterone or leuprolide.

Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.